WO2002074922A3 - Compositions and methods for modulating an immune response - Google Patents

Compositions and methods for modulating an immune response Download PDF

Info

Publication number
WO2002074922A3
WO2002074922A3 PCT/US2002/008207 US0208207W WO02074922A3 WO 2002074922 A3 WO2002074922 A3 WO 2002074922A3 US 0208207 W US0208207 W US 0208207W WO 02074922 A3 WO02074922 A3 WO 02074922A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immune response
modulating
compositions
immunomodulatory nucleic
Prior art date
Application number
PCT/US2002/008207
Other languages
French (fr)
Other versions
WO2002074922A2 (en
Inventor
David H Broide
Eyal Raz
Original Assignee
Univ California
David H Broide
Eyal Raz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, David H Broide, Eyal Raz filed Critical Univ California
Priority to AU2002248646A priority Critical patent/AU2002248646A1/en
Publication of WO2002074922A2 publication Critical patent/WO2002074922A2/en
Publication of WO2002074922A3 publication Critical patent/WO2002074922A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of maintaining suppression of a Th2 immune response, and methods of maintaining an increase in a Th1 immune response in an individual. The methods generally involve administering to an individual an effective amount of a first dose of a composition comprising an immunomodulatory nucleic acid, and, after a suitable time, administering at least a second dose of a composition comprising an immunomodulatory nucleic acid. The various aspects of the mammalian immune system involved in responses to immunomodulatory nucleic acids are depicted in the accompanying figure.
PCT/US2002/008207 2001-03-16 2002-03-15 Compositions and methods for modulating an immune response WO2002074922A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002248646A AU2002248646A1 (en) 2001-03-16 2002-03-15 Compositions and methods for modulating an immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27686501P 2001-03-16 2001-03-16
US60/276,865 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002074922A2 WO2002074922A2 (en) 2002-09-26
WO2002074922A3 true WO2002074922A3 (en) 2003-02-20

Family

ID=23058390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/008207 WO2002074922A2 (en) 2001-03-16 2002-03-15 Compositions and methods for modulating an immune response

Country Status (2)

Country Link
AU (1) AU2002248646A1 (en)
WO (1) WO2002074922A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1077722T3 (en) 1998-05-22 2006-11-27 Ottawa Health Research Inst Methods and products for the induction of mucosa immunity
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
PT1992635E (en) 2002-12-23 2012-03-20 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAY ET AL.: "Allergic diseases and their treatment", N. ENGL. J. MED., vol. 344, no. 2, 11 January 2001 (2001-01-11), pages 109 - 113 *
SEREBRISKY ET AL.: "CpG oligonucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma", J. OF IMMUNOL., vol. 165, no. 10, 2000, pages 5906 - 5912 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV

Also Published As

Publication number Publication date
AU2002248646A1 (en) 2002-10-03
WO2002074922A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
RS50325B (en) Immunostimulatory nucleic acids
FI962799A (en) Nucleic acid preparation, its preparation and use
WO2005016962A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
ATE355826T1 (en) METHOD FOR ENCAPSULATING NUCLEIC ACIDS IN LIPID DOUBLE LAYERS
EP2364716A3 (en) Compositions and methods for the treatment of natural killer cell related diseases
NZ504936A (en) Simultaneous administration of polynucleotide and delayed release polypeptide encoded by the polynucleotide to enhance an immune response of nucleic acid vaccination
WO2003028758A1 (en) Novel method of inducing antigen-specific t cells
CA2225797A1 (en) Active principle carriers containing non-ionic surfactants, and uses thereof, particularly in food, cosmetics and pharmaceuticals
AU4306896A (en) Method for the preparation of a viral vector by intermolecular homologous recombination
AU2482800A (en) Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
EP2322200A3 (en) Compositions and methods for the treatment of immune related diseases
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
CA2252604A1 (en) Methods of treating type i hypersensitivity using monophosphoryl lipid a
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
WO2000015179A3 (en) Cosmetic composition
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
MY115429A (en) Fenbendazole formulations
WO1999024077A3 (en) Compositions and methods for targeted delivery of biologically-active factors
WO2004069173A3 (en) Methods for modulating an inflammatory response
WO2002074922A3 (en) Compositions and methods for modulating an immune response

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP